All In Biotech

Drug Trial Radar · NCT07285460

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

An Open-label, Parallel, Phase 3, Two-arm Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B With or Without Inhibitory Antibodies to Factors VIII or IX

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

85

Planned (sponsor's estimate)

Start

Dec 18, 2025

Primary completion

Aug 4, 2029

Study completion Dec 30, 2031

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 1 year, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to \<12 years) who have severe hemophilia A or B, with or without inhibitory antibodies to FVIII or FIX. Number of participants: Approximately 85 participants will be enrolled into the study: * Approximately 60 fitusiran-naïve participants with severe hemophilia A or B, with or without inhibitors (fitusiran-naïve arm), and * Approximately 25 participants with severe hemophilia A or B with inhibitors rolling over from the EFC15467\* dose confirmation study (roll-over arm). * Fitusiran has been investigated in the pediatric population in study EFC15467, which enrolled male participants aged 1 to \<12 years with hemophilia A or B with inhibitors to examine the safety and tolerability of fitusiran in the pediatric population. Participants will be enrolled into 1 of 2 arms: * Fitusiran-naïve: these participants have not previously received fitusiran, and they will undergo screening and study eligibility assessments. Once enrolled, they will go through a 24-week standard of care (SOC) period before starting fitusiran prophylaxis. * Roll-over participants from the EFC15467 study: only participants who are still on active treatment in study EFC15467 and consenting to study EFC17905 will be eligible to roll over. They will not need to undergo screening or further eligibility assessments. They will directly enroll into the fitusiran treatment period and continue treatment on their current fitusiran dose. The duration of fitusiran treatment will be up to 160 weeks for the fitusiran-naïve arm and up to 60 weeks for the roll-over arm.

Conditions

  • Hemophilia

Interventions

  • FitusiranDrug

    Pharmaceutical form: solution for injection in PBS Route of administration: subcutaneous

  • Clotting factor concentrates (CFC) or bypassing agents (BPA)Biological

    Pharmaceutical form: solution for injection Route of administration: intravenous injection

  • Antithrombin concentrate (ATIIIC)Biological

    Pharmaceutical form: solution for injection Route of administration: intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized treated bleeding rate (ABR) in the fitusiran primary efficacy period and in the SOC periodTime frame: Day 85 to Day 421 (fitusiran primary efficacy period); Day -168 to Day -1 (SOC period)

Locations

37 sites in 12 countries. Site status is shown where the registry gives one.

  • The Luskin Orthopaedic Institute for Children- Site Number : 8400013

    Los Angeles, California · Recruiting

  • Children's Hospital Los Angeles- Site Number : 8400002

    Los Angeles, California · Recruiting

  • The Center for Inherited Blood Disorders- Site Number : 8400009

    Orange, California · Recruiting

  • UCLA Medical Center - Harbor- Site Number : 8400011

    Torrance, California · Recruiting

  • University of Michigan Health System - Ann Arbor- Site Number : 8400003

    Ann Arbor, Michigan · Recruiting

  • Cure 4 The Kids Foundation- Site Number : 8400001

    Las Vegas, Nevada · Recruiting

  • Hackensack Meridian Health - Hackensack University Medical Center- Site Number : 8400008

    Hackensack, New Jersey · Recruiting

  • University of Texas - Southwestern Medical Center- Site Number : 8400015

    Dallas, Texas · Recruiting

  • Investigational Site Number : 0560002

    Brussels, Belgium · Recruiting

  • Investigational Site Number : 0560001

    Brussels, Belgium · Recruiting

  • Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo- Site Number : 0760004

    São Paulo, Brazil · Recruiting

  • Universidade Estadual de Campinas (UNICAMP)- Site Number : 0760001

    Campinas, São Paulo, Brazil · Recruiting

  • Hospital das Clinicas da Faculdade de Medicina de Ribeirao Preto- Site Number : 0760003

    Ribeirão Preto, São Paulo, Brazil · Recruiting

  • Investigational Site Number : 1240001

    Hamilton, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240005

    Toronto, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240003

    Montreal, Quebec, Canada · Recruiting

  • Investigational Site Number : 1560001

    Beijing, China · Recruiting

  • Investigational Site Number : 1560002

    Wuhan, China · Recruiting

  • Investigational Site Number : 3560004

    Bengaluru, India · Recruiting

  • Investigational Site Number : 3560002

    Mumbai, India · Recruiting

  • Investigational Site Number : 3560001

    Pune, India · Recruiting

  • Investigational Site Number : 3560003

    Vellore, India · Recruiting

  • Investigational Site Number : 3800002

    Florence, Firenze, Italy · Recruiting

  • Investigational Site Number : 3800001

    Milan, Milano, Italy · Recruiting

  • Investigational Site Number : 3800003

    Rozzano, Milano, Italy · Recruiting

  • Investigational Site Number : 6160003

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

  • Klinika Transplantacji Szpiku, Onkologii i Hematologii Dziecięcej - Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wrocławiu-Site Number: 6160002

    Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting

  • Investigational Site Number : 6160001

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Investigational Site Number : 6820002

    Dammam, Saudi Arabia · Recruiting

  • Investigational Site Number : 6820001

    Riyadh, Saudi Arabia · Recruiting

  • Investigational Site Number : 7240003

    Zaragoza, Aragon, Spain · Recruiting

  • Investigational Site Number : 7240001

    Esplugues de Llobregat, Barcelona [Barcelona], Spain · Recruiting

  • Investigational Site Number : 7240002

    Madrid, Madrid, Comunidad de, Spain · Recruiting

  • Department of pediatrics, Chung Shan University Hospital-Site Number : 1580002

    Taichung, Taiwan · Recruiting

  • The division of Hematology, National Taiwan University Hospital-Site Number : 1580001

    Taipei City, Taipei, Taiwan · Recruiting

  • Investigational Site Number : 7920001

    Istanbul, Turkey (Türkiye) · Recruiting

  • Investigational Site Number : 7920002

    Izmir, Turkey (Türkiye) · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.